Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARE: Optune with Chemoradiotherapy in Glioblastoma
NCT03477110Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: NovoTTF-200A device discontinuation rate due to skin toxicity. Started May 2018; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03477110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03477110.